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Abstract
Introduction: Mobile technology, when included within multicomponent interventions, could contribute to more effective weight
loss. The objective of this project is to assess the impact of adding the use of the EVIDENT 3 application, designed to promote healthy
living habits, to traditional modification strategies employed for weight loss. Other targeted behaviors (walking, caloric-intake, sitting
time) and outcomes (quality of life, inflammatory markers, measurements of arterial aging) will also be evaluated.
Methods:Randomized, multicentre clinical trial with 2 parallel groups. The study will be conducted in the primary care setting and
will include 700 subjects 20 to 65 years, with a body mass index (27.5–40kg/m2), who are clinically classified as sedentary. The
primary outcomewill be weight loss. Secondary outcomeswill include change in walking (steps/d), sitting time (min/wk), caloric intake
(kcal/d), quality of life, arterial aging (augmentation index), and pro-inflammatory marker levels. Outcomes will be measured at
baseline, after 3 months, and after 1 year. Participants will be randomly assigned to either the intervention group (IG) or the control
group (CG). Both groups will receive the traditional primary care lifestyle counseling prior to randomization. The subjects in the IG will
be lent a smartphone and a smartband for a 3-month period, corresponding to the length of the intervention. The EVIDENT 3
application integrates the information collected by the smartband on physical activity and the self-reported information by participants
on daily food intake. Using this information, the application generates recommendations and personalized goals for weight loss.
Discussion: There is a great diversity in the applications used obtaining different results on lifestyle improvement and weight loss.
The populations studied are not homogeneous and generate different results. The results of this study will help our understanding of
the efficacy of new technologies, combined with traditional counseling, towards reducing obesity and enabling healthier lifestyles.
Ethicsanddissemination:The study was approved by the Clinical Research Ethics Committee of the Health Area of Salamanca
(“CREC of Health Area of Salamanca”) on April 2016. A SPIRIT checklist is available for this protocol. The trial was registered in
ClinicalTrials.gov provided by the US National Library of Medicine-number NCT03175614.
Abbreviations: BMI = body mass index, CG = control group, IG = intervention group, PAIx = peripheral augemtation index.
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1.1. The obesity problem
Obesity is growing epidemic in developed countries characterized
by elevated body mass index (BMI) and associated with
numerous health problems including cardiovascular issues
(e.g., stroke, coronary disease, hypertension, type 2 diabetes
mellitus).[1,2] Obesity exacerbates primary cardiovascular risk
factors (lipids, blood pressure, glucose, and inflammation)[3] and
contributes 20% of all mortalities[4] and 40% of mortalities due
to cardiovascular disease.[5]
The rapid increase in the prevalence of obesity, and its high
disease burden, strengthens the need to identify, implement, and
evaluate evidence-based interventions that address this prob-
lem.[6] The existing evidence does not support the use of low- or
moderate-intensity counselling alone in the treatment of obesi-
ty.[7]Whereas complex, multipronged interventions have resulted
in clinically significant weight loss (over 5%) in overweight and
obese adults.[8] Towards that end, the US Preventive Services
Task Force recommends these intensive interventions partially
because more patient contact in the first year results in greater,
more sustainable weight loss.[9]
1.2. Lifestyle and obesity
A healthy lifestyle has been associated with a lower prevalence of
obesity.[10] The positive effects of regular physical activity on
health and mortality are well established. Physical activity plays
an important role in the prevention of various chronic diseases,
such as cardiovascular disease, obesity, diabetes mellitus,
osteoporosis, and colon cancer.[11] However, in Europe, more
than half of the adult population does not achieve the
recommended levels of daily physical activity.[12] Furthermore,
sedentarism, defined as low levels of energy expenditure (1.5
MET basal metabolic rate), is related tomultiple health problems:
higher risk of diabetes, cardiovascular disease, cancer, and all
causes of death.[13] Generally, the most obesity-inducing lifestyle
choice is unhealthy eating habits. Diet has been directly
associated with the prevalence and development of obesity. In
this regard, the Western diet, characterized by high energy
density, high fat content, and low consumption of fiber, is
associated with higher rates of obesity,[14] including higher
plasma glucose levels and an unfavorable lipid profile.[15] On the
other hand, the Mediterranean diet is correlated with lower rates
of obesity in a population with high cardiovascular risk, which
results in reduced insulin resistance and less inflammation.[16]
1.3. Obesity and arterial aging
Obesity is associated with arterial health.[17] In the EVIDENT
study, sedentarism, low physical activity, and certain nutritional
patterns were found to correlate with hemodynamic measures of
arterial aging, such as the peripheral augmentation index
(PAIx).[18–20] There are numerous devices available for evaluat-
ing central hemodynamics,[21] including a wrist-worn tonometry
device developed by Microsoft Research[22] that are both easy
and convenient to use.
1.4. Mobile interventions for improving lifestyle and
weight loss
The use of smartphone applications applied to the field of
medicine is in progressive increase.[23] mHealth includes the use
of mobile phones, patient monitoring devices, and other wireless
systems that can be used in the prevention, diagnosis, and
treatment of chronic diseases including but not limited to type 2
diabetes and hypertension[24–26] in addition to promoting a
healthy lifestyle.[27] A recent meta-analysis showed that mobile
technology tools can result in amean reduction of 41minutes per
day of sitting time.[28] The potential of these applications to
change lifestyles in the population is very promising, but long-
term studies are needed to evaluate their efficacy over time.[29] A
review of the topic quantified the effect of these interventions as a
decrease of on average 1.44kg in body weight and of 0.24 units
on theBMI.[30] These values are very similar to those shown in the
review by Flores Mateo et al.[31] Taken together, these results
indicate that mobile interventions decrease adiposity (Evidence
Class IA)[29] with an efficacy dependent on and proportional to
the frequency with which they are used.[32]
1.5. Weight loss and quality of life
Interventions that aim to reduce obesity in adults through a
combination of diet and physical exercise have achieved
improvements in quality of life,[33] with sustainable long-term
effects (24 months). However, according to a recent meta-
analysis, these improvements were achieved primarily on a
physical level, not a mental one.[34]
In the previous study (EVIDENT 2), an improvement was
obtained in terms of increased self-reported physical activity and
an attributable effect in improving dietary habits in general
population,[35,36] using a smartphone application. In this study
protocol we present the third phase of the EVIDENT study where
the following developed version of the application will be used in
a population of special vulnerability due to its increased
cardiovascular risk, obese, or overweight people.
The objective of this research is to assess the impact of the
EVIDENT 3 application on weight loss when combined with
traditional primary care lifestyle modifications in overweight or
obese subjects. Secondary outcomes include changes in physical
activity, sedentarism, caloric intake, quality of life, arterial aging,
and pro-inflammatory markers.
2. Methods
2.1. Design and setting
This is a randomized, multicentre clinical trial with 2 parallel
groups. The study will be conducted in a primary care setting.
The Research Unit group from La Alamedilla Health Center,
Biomedical Research Institute of Salamanca (IBSAL), will
coordinate the project on 5 sites from the Network for Preventive
Activity and Health Promotion (REDIAPP) (Salamanca, Valla-
dolid, Cuenca, Palma de Mallorca, and Zaragoza).
2.2. Study population
All current patients of this 5 health centers will be eligible for this
study. Once inclusion/exclusion criteria are met (detailed below),
a healthcare professional will provide study subjects with oral
and written information about the study. Informed consent will
be obtained prior to any trial proceedings.
Inclusion criteria: subjects 20 to 65 years of age, BMI ≥27.5
and <40kg/m2, classified based on sedentarism (<3 20minutes
sessions of vigorous intensity physical activity per week; ≥5
30minutes sessions of moderate intensity physical activity
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[including walking] per week; or ≥5 sessions of any combination
of moderate and vigorous intensity physical activity).[37]
Exclusion criteria: subjects with any of the following
conditions will be excluded: musculoskeletal disease restricting
walking; low-calorie diet prescribed and/or controlled by a
healthcare professional or other weight loss program; use of other
applications with the objective to lose weight; bariatric surgery in
the past or planned in the next 12 months; treatment with any
pharmaceutical, natural, or homeopathic formulation for weight
loss; personal history of NYHA Grade II or higher heart
failure[38]; type 2 diabetes; oncological disease actively being
treated; terminal status; pregnancy; people living in the same
household as another study participant; other causes at the
investigator’s discretion that prevent inclusion.
2.3. Sample size
The sample size calculation was performed for the primary study
endpoint of weight loss. Accepting an a risk of 0.05 and a b risk
of 0.20, with an standard deviation (SD) of 12kg, estimated in
subjects from EVIDENT 2 study,[35] 592 subjects would be
needed (296 per group) to detect a decrease in weight of ≥3kg[39]
in the intervention group (IG) versus the control group (CG),
taking into consideration a 15% loss to follow-up. This effect size
represents a 3% to 5% difference between groups, which should
produce clinically relevant health benefits.[40] To minimize
dropouts, a reminder of the next visit will be provided at the
end of each visit, as well as 2 phone calls 15 and 5 days prior.
2.4. Randomization
Participants will be randomly assigned to either the IG or the CG.
Randomization will be performed after informed consent is
obtained. The allocation sequence will be generated through a
standardized computer programme (Epidat 4.2)[41] by an
independent researcher and concealed until the trial arms are
assigned.
2.5. Procedures
Each participant will complete an initial visit and 2 follow-up
visits at 3 and 12 months after study initiation (Fig. 1). Baseline
data will be collected by a research nurse. The IG will complete 2
additional appointments with a different nurse performing the
measurements. The first one will occur 7 days from the baseline in
which the application will be explained and the second one will
be during a phone call 15 days from the baseline visit to answer
any questions on how to use the application.
2.6. Primary and secondary outcomes
The primary outcome will be weight loss (kg). Secondary
outcomes will include change in the physical activity (steps/d)
measured by accelerometer, sitting time (min/wk), caloric intake
(kcal/d), quality of life, arterial aging, and pro-inflammatory
markers. All outcomes will be measured at baseline, 3, and 12
months after randomization.
2.6.1. Weight loss. Body weight will be measured twice, with
the subject barefoot and wearing light clothing, using a
homologated electronic balance (Scale 7830; Soehnle Profession-
al GmbH & Co, Backnang, Germany) after proper calibration
(precision±0.1kg). Height will be measured with the subject
barefoot in the standing position to record the average of
2 readings rounded to the nearest centimeter, using a portable
system (Seca 222; Medical scale and measurement system,
Birmingham, UK). BMI will be calculated by weight (kg) divided
by height squared (m2). Following the recommendations of the
Spanish Society for the Study of Obesity (SEEDO),[42] waist
circumference will be measured in duplicate, using a flexible tape
parallel to the floor, at the level of the midpoint between the last
rib and the iliac crest, with the subject standing without clothing,
after inspiration. Hip circumference will be similarly measured at
the level of the trochanters. Body composition will be determined
using an Inbody 230 analyzer[43] that estimates total body water,
dry lean mass, body fat mass, skeletal muscle mass, body fat
percentage, distribution of lean body mass, ratio of segmental
lean mass, and impedance of each body segment.
2.6.2. Physical activity. Physical activity will be measured using
both objective and subjective methods. Data from both self-
reported and objective methods will be analyzed and published in
study-derived manuscripts.
The primary means for quantifying physical activity objectively
will be the number of steps/d measured by an Actigraph GT3X
accelerometer (ActiGraph, Shalimar, FL), which has been
previously validated.[44] Output from the ActiGraph is in the
formof activity “counts,”where 1 count is equivalent to 16mgper
Figure 1. Study flowchart.
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second. Activity “counts” are recorded to the internal memory of
accelerometers by converting acceleration units over a given
period.[45] The change in the quantity and intensity of the physical
activity expressed in counts per minute, time dedicated to low,
moderate, and high/very vigorous activity will be determined. All
subjects included will wear the accelerometer on the right side of
thewaist, with an elastic band, for 7 consecutive days. Datawill be
recordedat1-minute intervals. The intensityof thephysical activity
(low,moderate, orhigh)will bedeterminedaccording to the cut-off
points proposed by Freedson et al,[46] sedentary activity (<100
counts/min), light (100–1952counts/min), moderate (1952–5724
counts/min), vigorous (5724–9498counts/min), and very vigorous
(>9498counts/min). The amount of physical exercise will be
estimated in MET/h/wk, and active persons will be engaging in at
least 30minutes ofmoderate activity 5 days perweek, or at least 20
minutes of vigorous activity 3 days per week, or who reach 450
MET/min/wk.[47] Criteria for considering an accelerometer session
to be valid include aminimumof 5 days, including at least 1 day of
the weekend. Sequences of≥10 consecutive zeros will indicate that
the participant has not worn the device and will not be taken into
account in the analysis.
The short version of the International Physical Activity
Questionnaire (IPAQ)[48] will be used to measure activity
subjectively. The IPAQ is a self-reported questionnaire that
evaluates sitting and active time in the last 7 days differentiating
between walking, moderate-intensity, and vigorous-intensity
activities, according to the energy expenditure estimated for
each of them (3.3, 4.0, and 8.0 metabolic equivalents of task
[MET], respectively). It allows the MET-min/wk to be calculated
and subjects to be classified according to 3 activity levels (low,
intermediate, and high).
2.6.3. Sedentary lifestyle. The sitting time (min/wk) will be
assessed using the ActivPal device. ActivPAL has been proven to
be a practical, reliable, and valid instrument for objectively
recording sedentary activity.[49] This device will be adhered to the
front of the thigh of each participant, between the knee and the
trunk, using an adhesive strip. Participants will use the devices for
7 days at each follow-up visit (baseline, 3, and 12 months). This
device is used to estimate the average minutes of activity per day,
average minutes spent sitting per day, and average number of
steps per day. We will use cut-off points for the categorization of
the sedentary behavior (0–5counts/15s) collected through the
ActivPal devices, as proposed by Atkin et al.[50]
2.6.4. Caloric intake. Caloric intake (kcal/d) and dietary habits
of participants will be evaluated using a semi-quantitative food-
frequency questionnaire previously validated in Spain.[51] The
estimated frequency corresponds to the previous year at the time
of the interview and is based on the typical portion sizes
multiplied by the consumption frequency for each food. This
value is then divided into 9 intake categories ranging from never
to >6 servings/d. This will be used to estimate daily intake of
macro- and micro-nutrients. Adherence to the Mediterranean
diet will be assessed using the validated 14-point Mediterranean
Diet Adherence Screener (MEDAS),[52] developed by the
PREDIMED study group, which explores compliance with
various aspects considered characteristic of the Mediterranean
diet. Adequate adherence will be assumed when the total score is
9 points or higher.
2.6.5. Quality of life. Quality of life will be measured using the
IWQoL-Lite (Impact of Weight on Quality of Life-Lite). This
questionnaire is made up of 31 self-reported items, each of which
is scored between 1 (“never true”) and 5 (“always true”). Specific
scores are obtained in 5 domains: physical function (11 items),
self-esteem (7 items), sexual life (4 items), public distress (5 items),
and work (4 items). Higher scores are associated with better
quality of life. The original version proved to have good internal
consistency (≥0.90), test–retest reliability (≥0.83), and sensitivity
to change.[53]
2.6.6. Arterial aging. The central and peripheral augmentation
index will be measured using a novel wrist-worn device
developed by Microsoft Research. Participants will be examined
in a seated position after 10minutes of rest. The subject’s armwill
be supported on a firm surface at heart-height. The wrist-worn
device non-invasively senses multiple physiological signals
associated with cardiovascular health. The device includes an
applanation tonometer placed over the radial artery, an
electrocardiogram, a 3-axis accelerometer, and a 3-axis gyro-
scope. It is capable of performing continuous or scheduled
measurements using various configurations of these sensors and it
includes Bluetooth for data streaming.[54] Cardio-ankle vascular
index (CAVI), brachial-ankle pulse wave velocity (ba-PWV), and
ankle-brachial index (ABI) will be measured at rest, using the
Vasera device VS-2000 (Fukuda Denshi).
2.6.7. Pro-Inflammatory markers. A centralized laboratory
will measure levels of IL-1b, IL-7, and adiponectin, as they are
considered pro-inflammatory markers related to obesity.[55]
Venous blood sampling will be performed between 8:00 am and
9:00 am after participants have fasted and abstained from
smoking, consumption of alcohol, and caffeinated beverages for
12hours. Other laboratory determinations, such as plasma
glucose, creatinine, total serum cholesterol, high-density lipopro-
tein (HDL) cholesterol, low-density lipoprotein (LDL) cholester-
ol, and triglyceride concentrations will be determined using
standard automated enzymatic methods. Glycosylated hemoglo-
bin, high-sensitivity C-reactive protein levels, insulinemia, and
fibrinogen values will be measured with an immune-turbidimetric
assay. An ELISA will be used to determine the levels of thyroid-
stimulating hormone (TSH) and free T4 hormone. Spot morning
urine samples will be collected to determine the albumin–
creatinine ratio. The analyses will be performed at the hospitals in
the cities participating in external quality assurance programs of
the Spanish Society of Clinical Chemistry and Molecular
Pathology.
2.6.8. Other variables. Sociodemographic variables: At the time
of inclusion in the study, data on age, sex, marital status,
educational level, and occupation will be collected.
Peripheral blood pressure: Three measurements of systolic
(SBP) and diastolic (DBP) blood pressure will be performed using
the average of the last 2 with a validated Omron M10-IT model
sphygmomanometer (Omron Healthcare, Kyoto, Japan). The
measurements will be made on the participant’s dominant arm in
a seated position after at least 5minutes of rest with a cuff of
appropriate size, as determined bymeasurement of the upper arm
circumference and following the recommendations of the
European Society of Hypertension.[56]
Smoking status: This will be assessed through a questionnaire
of 4 standard questions adapted from the WHO MONICA
study.[57] Study participants will be classified as current smokers
or non-smokers (never or >1 year without smoking).
Motivation to change:Wewill use themotivation stage according
to the transtheoretical model of change (TTM)—Prochaska and
DiClementemodel (pre-contemplation,contemplation,preparation,
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action, maintenance, and relapse).[58] TTM constructs will be
measured only when relating to weight loss.
2.7. Intervention
2.7.1. Standard counselling (CG and IG). Both groups (control
and intervention) will receive 5minutes of counselling at the end
of the baseline visit and prior to randomization. Advice on
physical activity will be in compliance with the current
international recommendations for the general population. The
health benefits of physical activity and the recommendation to
complete at least 30minutes of moderate activity 5 days a week,
or 20minutes of vigorous activity 3 days a week, will be
explained. Counselling on food will be in compliance with the
plate method,[59] in which a plate is divided into 4 parts: half the
plate for salad or vegetables, one fourth for proteins (white meat
preferred over red meat), and the final fourth for carbohydrates.
In addition, a medium-sized piece of fruit and a skimmed dairy
product should be consumed for dessert.
2.7.2. Specific intervention (IG). The IG will be lent a
smartphone and a smartband (Xiaomi Miband 2), for a 3-
month period, corresponding to the length of the intervention. A
baseline visit will be completed, lasting approximately 15
minutes, in which the subjects will be trained to use the device
and the application (EVIDENT 3 Application, [record entry no.
00/2017/2438]) specifically designed for the study (Fig. 2). In the
first part of this visit, the application will be configured with each
participant’s data (sex, age, weight, and height). The application
design allows for full daily control of food intake and physical
activity performed (more details in Supplementary Material,
http://links.lww.com/MD/C76). The application collects the
information gathered by the smartband on physical activity,
calories, number of steps, number of hours walking, and the
information gathered by the subject on daily food intake. Once all
the daily information is collected, the application integrates the
data to create, based on the subject’s characteristics, personalized
recommendations, and specific objectives and goals for weight
loss. A new visit will take place the week the device is provided, to
confirm it is being used properly and to answer any questions. At
the 3-month visit, the devices will be collected. All information
generated by the application will be duly analyzed and entered in
the database. We will evaluate the usability and acceptability of
the application[60] after completing the 3-month assessment visit
only for IG subjects. A questionnaire will be used to evaluate the
application’s ease of use, need for training by expert personnel,
level of complexity, and its consistency.
2.7.3. Blinding strategy. The investigator carrying out the
intervention with the IG will be different from the person
responsible for the assessment and the standard counselling; both
will be kept blinded throughout the study, as will the investigator
conducting the data analysis. The subjects, due to the nature of
the study, cannot be blinded. To prevent contamination between
groups, in the assessment visits (3 and 6 months), only the study
variables will be evaluated but no advice or reinforcement will be
given. In addition, the application will not be available for
download on the web until the end of the study so the CGwill not
be able to make use of it in any way. During the follow-up visits,
participants will be instructed not to use other health technolo-
gies. Compliance will be ensured by a brief question about the use
of other applications and mHealth technology.
2.8. Statistical analysis
2.8.1. General analysis. Results will be expressed as mean±
standard deviation for quantitative variables normally distribut-
ed or medians (interquartile ranges) for the skewed variables and
by frequency distribution for qualitative variables. The statistical
normality will be tested using the Kolmogorov–Smirnov test. The
Chi-square test and Fisher exact test will be used to analyze
the association between independent qualitative variables. The
Student’s t test or Mann–Whitney U test will be used for the
comparison of means between 2 independent groups. Pearson
Figure 2. Screenshots of the EVIDENT 3 application.
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correlation or Rho de Spearman will be used to evaluate the
relationships between quantitative variables.
The main analysis of primary and secondary outcomes will be
performed on an intent-to-treat basis. We will also perform a
secondary analysis according to the different levels of adherence
to the use of the application (low adherence: <2 months; high
adherence: ≥2 months) and according to relevant subgroups.
Multiple imputations will be used to address missing values in the
dataset.
2.9. Analysis of intervention effect in primary and
secondary outcomes
To analyze the changes, at 3 and 12 months from baseline, in
primary (weight loss) and secondary endpoints within the same
group, we will use the paired t test or McNemar test for
quantitative or dichotomy variables, respectively.
To analyze the effect of the intervention, we will compare the
changes from baseline observed between the IG and CG in weight
(primary endpoint) and secondary endpoints, usingANCOVAat3
and 12 months, adjusting for baseline measures of each variable.
In order to analyze the group effect in the follow-up for
primary and secondary endpoints, we will perform a multivariate
analysis of the variance of repeated measures, adjusted by the
baseline value of each variable. Any interaction between the
primary and secondary endpoints with the group (IG vs CG) and
Cohen d will be estimated.
2.10. Analysis of effect by adherence
To assess the effect of adherence to the application, we will divide
the IG into high adherence (≥2 months), and low adherence (<2
months), according to the specified criteria, and the same analysis
as previously described will be performed.
2.11. Analysis by subgroups
The impact of the intervention could be also affected by age,
cultural and socioeconomic level, and certain diseases, which will
all be analyzed by specific subgroups as previously described. An
analysis will be performed to assess differences between men and
women for adherence to the application and results in the short
term (3 months) and long term (12 months).
2.12. Secondary analysis
A multivariate analysis of multiple linear regressions will be
performed to identify the variables that most influence changes in
weight, physical activity, sedentarism, and arterial stiffness.
Continuous information, nutrition, and physical activity, over
the 3 months of use of the application and the Smartband, will be
collected in the IG. Data will be grouped by week to observe their
evolution and compare the changes in these parameters with
changes in the main variables (body weight, physical activity, and
arterial stiffness).
All statistical analyses will be performed with SPSS version
23.0 (IBM Corp, Armonk, NY), with the level of statistical
significance set at P .05.
2.13. Ethics and dissemination
The study was approved by the Clinical Research Ethics
Committee of the Health Area of Salamanca (“CREC of Health
Area of Salamanca”) in April 2016. In addition, the study was
approved by the Ethics Committees of the 4 collaborating centres
(CEIC de Aragón [CEICA], CEIC de Castilla laMancha, CEIC de
Baleares and CEIC de Area de Salud de Valladolid Oeste). A
SPIRIT checklist is available for this protocol. The trial has been
registered in ClinicalTrials.gov with identifier NCT03175614.
Participants must sign the informed consent before inclusion in
the study in accordance with the Declaration ofHelsinki. Subjects
will be informed about the objectives of the study and the risks
and benefits of the examinations that they will undergo, including
sample collection. None of the testing could result in life-
threatening risks for the subjects. Subject confidentiality will be
ensured at all times in accordance with current laws and
regulations on personal data protection (LOPD 15/1999 of 13
December 1999) as well as the conditions described in Act 14/
2007 on biomedical research.
3. Discussion
The studies available that quantify the effect of smartphone
applications (mHealth) on weight loss are increasing. There is a
great diversity in the applications used obtaining different results
on lifestyle improvement. These mHealth interventions have
small to moderate effects on physical activity and sedentary
behavior.[61] Recent evidence suggests that applications must
include a detailed registration of foods, goals, and customizable
challenges and also incorporate personalized feedback and
recommendations.[62] Finally, the populations studied are not
homogeneous, and therefore generate different results depending
on age, sex, and morbidities. Therefore, it is expected that the
results of this study will further our understanding of the efficacy
of new technologies, combined with traditional counselling,
towards reducing obesity and enabling healthier lifestyles.
3.1. Methodological limitations
Because of the nature of the intervention, participating subjects
cannot be blinded. However, towards achieving the greatest
possible blinding effect, neither the person performing the
statistical analysis nor the person measuring study variables will
know to which group each participant belongs. Even though the
analysis of some of the results regarding the modification of
lifestyle will be performed using self-reported data, validated
tools will be used. However, objective data, such as accelerometer
for physical activity and weight and body composition
measurement, will compliment subjective results. Any difficulties
involved in the use of the application may result in an increase in
the number of dropouts from the IG.
3.2. Dissemination plan
We will use a variety of methods to ensure that our work will
achieve maximum visibility. The publication of our study
protocol provides an important first step in this direction. In
this paper, we have sought to offer a comprehensive overview of
relevant literature while underlining current research gaps that
necessitated the design and implementation of the EVIDENT 3
study. The study results, given their applicability and implications
for the general population, will be disseminated in investigator
meetings and in articles published in peer-reviewed scientific
journals. Minimally, one manuscript is planned for publication
with main findings and sub-analyses (in SupplementaryMaterial,
http://links.lww.com/MD/C76) and one manuscript for the
secondary findings. In addition, a proposal for a doctoral thesis
based on this project has been made.
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